Announcements Trials
Browse Landscape

Phase

Phase 1/2 1

Status

Recruiting 1

Sponsor Class

OTHER 1

Study Type

Interventional 1

Sponsor

Cancer Type

Other hematologic neoplasm 81Lymphoid 56Myeloid 51Plasma cell 19Classical hematology 12CNS 8Sarcoma 7Dermatologic 5Gynecologic 2Genitourinary 2Breast 2Other neoplasm 1

Conditions

Non-Malignant Neoplasm 1

Interventions

Surveys and Questionnaires 9Cyclophosphamide 9Whole-Body Irradiation 7Biopsy 7fludarabine phosphate 6Peripheral Blood Stem Cell Transplantation 6Educational Status 6Early Intervention, Educational 6Busulfan 6Methotrexate 5Methods 5Immunohistochemistry 5Epoetin Alfa 5Tacrolimus 4Mycophenolic Acid 4Interviews as Topic 4Gene Expression Profiling 4Decitabine 4Cyclosporine 4Celecoxib 4Antilymphocyte Serum 4fludarabine 3Sirolimus 3Radiotherapy 3Paclitaxel 3Microarray Analysis 3Melphalan 3Magnetic Resonance Spectroscopy 3Imiquimod 3Fentanyl 3

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
OTHER × thymoglobulin × Other neoplasm × Clear all
NCT04083183 2025-12-18

Total Body Irradiation and Astatine-211-Labeled BC8-B10 Monoclonal Antibody for the Treatment of Nonmalignant Diseases

Fred Hutchinson Cancer Center

Phase 1/2 Recruiting
40 enrolled
Other neoplasm

Non-Malignant Neoplasm

Data powered by HemOnc (CC BY 4.0) Colophon âš¡